{"id":"apo-clonidine","safety":{"commonSideEffects":[{"rate":"40","effect":"Dry mouth"},{"rate":"33","effect":"Drowsiness"},{"rate":"16","effect":"Dizziness"},{"rate":"10","effect":"Constipation"},{"rate":null,"effect":"Rebound hypertension (upon discontinuation)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clonidine binds to alpha-2 adrenergic receptors in the central nervous system, decreasing the release of norepinephrine and reducing sympathetic outflow. This results in decreased peripheral vascular resistance and lower blood pressure. It is also used off-label for conditions involving sympathetic hyperactivity such as ADHD and opioid withdrawal.","oneSentence":"Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity, lowering blood pressure and heart rate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:41.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Attention-deficit/hyperactivity disorder (off-label)"},{"name":"Opioid withdrawal (off-label)"}]},"trialDetails":[{"nctId":"NCT00152750","phase":"PHASE4","title":"Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2006-09","conditions":"Tourette's Syndrome, Attention Deficit Hyperactivity Disorder","enrollment":32}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"WEIGHT INCREASED"},{"count":3,"reaction":"ARTHRALGIA"},{"count":3,"reaction":"FALL"},{"count":3,"reaction":"FATIGUE"},{"count":3,"reaction":"HEADACHE"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"DEATH"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"DRUG INEFFECTIVE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"APO-clonidine","genericName":"APO-clonidine","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity by stimulating alpha-2 receptors in the brain and periphery. Used for Hypertension, Attention-deficit/hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}